Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance

Christina M. Medina-Ramirez, Sumanta Goswami, Tatiana Smirnova, Daniel Bamira, Benjamin Benson, Neal Ferrick, Jeffrey E. Segall, Jeffrey W. Pollard, Richard N. Kitsis

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Apoptosis repressor with caspase recruitment domain (ARC) inhibits both death receptor- and mitochondrial/ER-mediated pathways of apoptosis. Although expressed mainly in terminally differentiated cells, ARC is markedly upregulated in a variety of human cancers, where its potential contributions have not yet been defined. In this study, we provide evidence of multiple critical pathophysiologic functions for ARC in breast carcinogenesis. In the polyoma middle T-antigen (PyMT) transgenic mouse model of breast cancer, in which endogenous ARC is strongly upregulated, deletion of the ARC-encoding gene nol3 decreased primary tumor burden without affecting tumor onset or multiplicity. More notably, ARC deficiency also limited tumor cell invasion and the number of circulating cancer cells, markedly reducing the number of lung metastases. Conversely, ectopic overexpression of ARC in a PyMT-derived metastatic breast cancer cell line increased invasion in vitro and lung metastasis in vivo. We confirmed these results in a humanized orthotopic model based on MDA-MB-231-derived LM2 metastatic breast cancer cells, in which RNAi-mediated knockdown of ARC levels was shown to reduce tumor volume, local invasion, and lung metastases. Lastly, we found that endogenous levels of ARC conferred chemoresistance in primary tumors and invading cell populations. Our results establish that ARC promotes breast carcinogenesis by driving primary tumor growth, invasion, and metastasis as well as by promoting chemoresistance in invasive cells.

Original languageEnglish (US)
Pages (from-to)7705-7715
Number of pages11
JournalCancer Research
Volume71
Issue number24
DOIs
StatePublished - Dec 15 2011

Fingerprint

AIDS-Related Complex
Carcinogenesis
Breast
Apoptosis
Neoplasm Metastasis
Neoplasms
Viral Tumor Antigens
Breast Neoplasms
Tumor Burden
Lung
Death Domain Receptors
RNA Interference
Transgenic Mice
Cell Count

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Medina-Ramirez, C. M., Goswami, S., Smirnova, T., Bamira, D., Benson, B., Ferrick, N., ... Kitsis, R. N. (2011). Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance. Cancer Research, 71(24), 7705-7715. https://doi.org/10.1158/0008-5472.CAN-11-2192

Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance. / Medina-Ramirez, Christina M.; Goswami, Sumanta; Smirnova, Tatiana; Bamira, Daniel; Benson, Benjamin; Ferrick, Neal; Segall, Jeffrey E.; Pollard, Jeffrey W.; Kitsis, Richard N.

In: Cancer Research, Vol. 71, No. 24, 15.12.2011, p. 7705-7715.

Research output: Contribution to journalArticle

Medina-Ramirez, CM, Goswami, S, Smirnova, T, Bamira, D, Benson, B, Ferrick, N, Segall, JE, Pollard, JW & Kitsis, RN 2011, 'Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance', Cancer Research, vol. 71, no. 24, pp. 7705-7715. https://doi.org/10.1158/0008-5472.CAN-11-2192
Medina-Ramirez CM, Goswami S, Smirnova T, Bamira D, Benson B, Ferrick N et al. Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance. Cancer Research. 2011 Dec 15;71(24):7705-7715. https://doi.org/10.1158/0008-5472.CAN-11-2192
Medina-Ramirez, Christina M. ; Goswami, Sumanta ; Smirnova, Tatiana ; Bamira, Daniel ; Benson, Benjamin ; Ferrick, Neal ; Segall, Jeffrey E. ; Pollard, Jeffrey W. ; Kitsis, Richard N. / Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance. In: Cancer Research. 2011 ; Vol. 71, No. 24. pp. 7705-7715.
@article{4b69e4380d164096ad48fcf91b3f872e,
title = "Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance",
abstract = "Apoptosis repressor with caspase recruitment domain (ARC) inhibits both death receptor- and mitochondrial/ER-mediated pathways of apoptosis. Although expressed mainly in terminally differentiated cells, ARC is markedly upregulated in a variety of human cancers, where its potential contributions have not yet been defined. In this study, we provide evidence of multiple critical pathophysiologic functions for ARC in breast carcinogenesis. In the polyoma middle T-antigen (PyMT) transgenic mouse model of breast cancer, in which endogenous ARC is strongly upregulated, deletion of the ARC-encoding gene nol3 decreased primary tumor burden without affecting tumor onset or multiplicity. More notably, ARC deficiency also limited tumor cell invasion and the number of circulating cancer cells, markedly reducing the number of lung metastases. Conversely, ectopic overexpression of ARC in a PyMT-derived metastatic breast cancer cell line increased invasion in vitro and lung metastasis in vivo. We confirmed these results in a humanized orthotopic model based on MDA-MB-231-derived LM2 metastatic breast cancer cells, in which RNAi-mediated knockdown of ARC levels was shown to reduce tumor volume, local invasion, and lung metastases. Lastly, we found that endogenous levels of ARC conferred chemoresistance in primary tumors and invading cell populations. Our results establish that ARC promotes breast carcinogenesis by driving primary tumor growth, invasion, and metastasis as well as by promoting chemoresistance in invasive cells.",
author = "Medina-Ramirez, {Christina M.} and Sumanta Goswami and Tatiana Smirnova and Daniel Bamira and Benjamin Benson and Neal Ferrick and Segall, {Jeffrey E.} and Pollard, {Jeffrey W.} and Kitsis, {Richard N.}",
year = "2011",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-11-2192",
language = "English (US)",
volume = "71",
pages = "7705--7715",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Apoptosis inhibitor ARC promotes breast tumorigenesis, metastasis, and chemoresistance

AU - Medina-Ramirez, Christina M.

AU - Goswami, Sumanta

AU - Smirnova, Tatiana

AU - Bamira, Daniel

AU - Benson, Benjamin

AU - Ferrick, Neal

AU - Segall, Jeffrey E.

AU - Pollard, Jeffrey W.

AU - Kitsis, Richard N.

PY - 2011/12/15

Y1 - 2011/12/15

N2 - Apoptosis repressor with caspase recruitment domain (ARC) inhibits both death receptor- and mitochondrial/ER-mediated pathways of apoptosis. Although expressed mainly in terminally differentiated cells, ARC is markedly upregulated in a variety of human cancers, where its potential contributions have not yet been defined. In this study, we provide evidence of multiple critical pathophysiologic functions for ARC in breast carcinogenesis. In the polyoma middle T-antigen (PyMT) transgenic mouse model of breast cancer, in which endogenous ARC is strongly upregulated, deletion of the ARC-encoding gene nol3 decreased primary tumor burden without affecting tumor onset or multiplicity. More notably, ARC deficiency also limited tumor cell invasion and the number of circulating cancer cells, markedly reducing the number of lung metastases. Conversely, ectopic overexpression of ARC in a PyMT-derived metastatic breast cancer cell line increased invasion in vitro and lung metastasis in vivo. We confirmed these results in a humanized orthotopic model based on MDA-MB-231-derived LM2 metastatic breast cancer cells, in which RNAi-mediated knockdown of ARC levels was shown to reduce tumor volume, local invasion, and lung metastases. Lastly, we found that endogenous levels of ARC conferred chemoresistance in primary tumors and invading cell populations. Our results establish that ARC promotes breast carcinogenesis by driving primary tumor growth, invasion, and metastasis as well as by promoting chemoresistance in invasive cells.

AB - Apoptosis repressor with caspase recruitment domain (ARC) inhibits both death receptor- and mitochondrial/ER-mediated pathways of apoptosis. Although expressed mainly in terminally differentiated cells, ARC is markedly upregulated in a variety of human cancers, where its potential contributions have not yet been defined. In this study, we provide evidence of multiple critical pathophysiologic functions for ARC in breast carcinogenesis. In the polyoma middle T-antigen (PyMT) transgenic mouse model of breast cancer, in which endogenous ARC is strongly upregulated, deletion of the ARC-encoding gene nol3 decreased primary tumor burden without affecting tumor onset or multiplicity. More notably, ARC deficiency also limited tumor cell invasion and the number of circulating cancer cells, markedly reducing the number of lung metastases. Conversely, ectopic overexpression of ARC in a PyMT-derived metastatic breast cancer cell line increased invasion in vitro and lung metastasis in vivo. We confirmed these results in a humanized orthotopic model based on MDA-MB-231-derived LM2 metastatic breast cancer cells, in which RNAi-mediated knockdown of ARC levels was shown to reduce tumor volume, local invasion, and lung metastases. Lastly, we found that endogenous levels of ARC conferred chemoresistance in primary tumors and invading cell populations. Our results establish that ARC promotes breast carcinogenesis by driving primary tumor growth, invasion, and metastasis as well as by promoting chemoresistance in invasive cells.

UR - http://www.scopus.com/inward/record.url?scp=84255170353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84255170353&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-2192

DO - 10.1158/0008-5472.CAN-11-2192

M3 - Article

C2 - 22037876

AN - SCOPUS:84255170353

VL - 71

SP - 7705

EP - 7715

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 24

ER -